BioSkryb Genomics Names Dr. William Evans as CEO

BioSkryb Genomics, a pioneer in single-cell and ultra-low-input multiomic solutions, has appointed William E. Evans, Pharm.D. as Chief Executive Officer (CEO).

Evans has served on BioSkryb’s Board of Directors and as Chair of its Scientific Advisory Board since 2019. He succeeds Suresh Pisharody, who has departed the company to pursue other opportunities.

“We are delighted to have Bill transition from SAB Chair into the CEO role,” said BioSkryb’s scientific founder Charles Gawad, MD/Ph.D. “I have worked with Bill over the past decade, first as a collaborator on drug resistance in childhood acute lymphoblastic leukemia, then with his roles at BioSkryb. I cannot think of a more capable scientific leader to help us realize the full potential of our technologies for basic science and translational research, and now, emerging clinical applications. I look forward to working with him to enable BioSkryb’s continued growth.”

Experience

Evans has been closely involved with BioSkryb Genomics since 2019. He brings four decades of leadership in pediatric oncology research, pharmacogenomics, and translational research to the role. He joined the faculty of St. Jude Children’s Research Hospital in 1976, founded and chaired its Pharmaceutical Sciences Department (1986–2002), and served as the hospital’s Scientific Director and Executive Vice President before becoming President and Chief Executive Officer of St. Jude for a decade (2004–2014). He held the St. Jude Endowed Chair of Pharmacogenomics, is a Professor at the University of Tennessee Colleges of Medicine and Pharmacy and became Emeritus faculty in 2021.

Evans’ past research has focused on the pharmacodynamics and pharmacogenomics of anticancer agents in children. He has authored more than 450 publications and received numerous national honors, including the 2009 Pediatric Oncology Award from ASCO, the 2009 Team Science Prize from AACR, the 2012 Remington Medal and the 2016 Parker Medal. He is a member of the National Academy of Medicine and the German National Academy of Sciences. He previously served on the Board of Directors of Accredo Health.

“I’m honored to step into this role and drive our business forward into major clinical applications, AI-oriented multiomic cell atlas programs, and expansions of our customer’s transformative basic biomedical research in oncology, neurology, and cell and gene therapy,” Evans said. “I look forward to working closely with our current and new customers and partners worldwide.”